Is this specific to KLOW?

No, it applies to any fixed-ratio mixture of molecules with different stability, which is nearly all of them. It is more pronounced here because four components span a wide range of size and structural protection.

Do any of these have published half-life figures?

The individual literatures contain stability and persistence information of varying quality, generated in different systems under different conditions. None of it was generated with the components in combination, which is the situation a blend creates.

Could the components stabilise each other?

That is a real possibility in principle - competition for the same peptidases would slow all of them - and it is untested here. It would push in the opposite direction to the divergence described above, which is a reason to measure rather than to assume either way.

Does this affect storage as well?

Storage is a separate and better-understood problem, covered elsewhere in this category. The point here concerns what happens after a solution leaves the vial, where the conditions are no longer controlled by handling.

KLOW (Blend)

The Ratio in the Vial Is Not the Ratio Anything Sees

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-244 cited sources

Whatever ratio a blend contains holds only at the instant it is administered. From that point each component follows its own degradation and clearance, so the proportions present at any later time differ from the label and differ again at every subsequent time.

Key facts

Components: 4, spanning 342 to 1,420 daltons
Ratio fixed at: The moment of dosing only
What changes it afterwards: Differential degradation and clearance
Structural feature slowing degradation: Proline content, backbone modification, acetylation
KPV: Contains proline; three residues
GHK-Cu: Tripeptide bound to a metal ion
TB-500: N-acetylated heptapeptide
BPC-157: 15 residues, proline-rich

What a fixed ratio actually fixes

The appeal of a co-formulation is that the proportions are decided once and cannot drift. That is true of the vial and false of everything downstream. A blend fixes the ratio at a single instant - the moment of administration - and controls nothing afterwards. From that instant each component is subject to its own peptidases, its own binding, its own distribution and its own elimination, all of which differ. The ratio at one hour is not the ratio in the vial, the ratio at six hours is not the ratio at one hour, and neither is stated or knowable from the label.

Why the four should be expected to differ

Peptide persistence is governed by a small number of structural features, and these four differ on most of them. Length matters, because more peptide bonds means more sites for cleavage, though longer peptides can also adopt structures that shield the backbone. Proline is protective: its ring constrains the backbone and most peptidases cannot cleave adjacent to it, which is why proline-rich sequences persist longer than their length suggests. N-terminal acetylation removes the free amine that aminopeptidases require, which is precisely why TB-500 is supplied acetylated. And a chelated metal ion changes both the molecule's conformation and its interactions with plasma proteins. Four components, four different combinations of these features, four different persistence profiles.

Research material referenced

KLOW 80mg — third-party HPLC tested

View — £69.99

The consequence for interpreting a result

Suppose a blend produces an effect. Attributing it to the combination assumes the combination was present as such. If one component has largely disappeared by the time the measured effect occurs, the effect belongs to whatever remained - which may be one or two components rather than four. Conversely, an effect measured early may reflect a composition close to the label while an effect measured late reflects something quite different. The timing of the measurement therefore silently selects which mixture is being tested, and nothing about the format makes that visible.

Why this is harder to reason about than dissolution

Uneven dissolution is a known feature of co-lyophilised blends and it has an answer: swirl rather than shake, allow time, and the components eventually all go into solution. Differential clearance has no such fix. It is not a handling error to be corrected but a property of the molecules, and it cannot be designed away within a fixed-ratio format. The only formats that avoid it are a single molecule carrying multiple activities - which is what a dual or triple agonist is - or separate administration on separate schedules, which is what a blend exists to avoid.

What would have to be measured

A per-component concentration-time profile in the same system, from the same administered blend. That means an assay capable of quantifying each of the four separately in the presence of the other three, at concentrations falling over time, with a stated per-component starting mass. The first requirement is achievable - these four have well-separated molecular weights - and the last is not, because the split is not stated. No such work exists for this combination, and none exists for any peptide blend of this kind that this library has found.

How to hold this when reading about blends

As a structural limitation rather than a defect. The blend format buys convenience and a reproducible starting composition, and it cannot buy a stable composition over time because no fixed mixture of different molecules has one. That is worth knowing before drawing conclusions from a blend result, and it is a reason to be sceptical of any claim about what the four do together, which would require knowing that the four were together when it happened. All four components are supplied for laboratory research only and none holds a marketing authorisation.

Extended research context

The KLOW (Blend) deep dive

Deep dive: a fourfold size range in one cake, and what partial dissolution hides

KLOW's components run from KPV at 342.43 daltons to BPC-157 at 1419.5 - a fourfold span, and the widest of any product in this catalogue. Solubility depends on size, charge distribution and hydrophobicity, and these four differ in all three, so a co-lyophilised cake containing all of them releases its components in sequence rather than together. The hazard follows directly and is easy to miss: a cake that looks partly dissolved is not uniformly partly dissolved. The smallest component may be entirely in solution while the largest has barely started. Draw from the vial at that moment and the sample is enriched in the fast components and depleted in the slow ones - a composition error with no visible sign at all, since the liquid looks like liquid. The instinctive response to visible solid makes it worse: shaking creates air-liquid interfaces, which is exactly where peptides unfold and then aggregate irreversibly. The correct response is diluent down the vial wall, gentle swirling, and more patience than a single peptide or even a three-component blend requires. There is a second asymmetry on top. Small peptides adsorb to glass and plastic more readily than large ones, so KPV is the component most likely to be lost to container walls at low concentration - a silent shift in the effective ratio that no certificate figure accounts for.

Deep dive: the cleanest possible comparison, which still cannot be run

KLOW is a strict superset of GLOW - the same three components plus KPV, at 80 mg against 70 mg. Product comparisons rarely have this structure. There is nothing in GLOW that KLOW lacks, so the difference between them reduces to a single question rather than a balance of trade-offs, and in principle comparing the two would isolate exactly what KPV contributes. In practice it cannot be done. The 10 mg difference in total might be 10 mg of added KPV with the other three unchanged, or it might be a redistribution across all four; both are consistent with the published figures, and neither product states its split. So any difference observed between the two could be KPV, or it could be a changed concentration of GHK-Cu, BPC-157 or TB-500. The experiment that the product pairing seems designed to permit is precisely the one the missing information forbids. This is the fixed-ratio limitation in its sharpest form: not that the format is unhelpful in general, but that it withholds the one number that would make the most natural question answerable.

Deep dive: two products from one hormone, in categories that never mention each other

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, isolated because that hormone does two functionally separable things - pigmentation through melanocortin receptors, and anti-inflammatory activity localised to its C-terminal end. KPV keeps the second and discards the first. Now look elsewhere in this catalogue: MT-2 is also an alpha-MSH derivative, and it is built around the melanocortin-receptor-binding core that KPV was specifically designed to leave behind. Two products, one parent hormone, opposite halves of its function, sitting in entirely separate product categories with nothing in either listing to indicate they are related. The size difference tracks the design logic. KPV at 342.43 daltons is three residues with no modifications, because an effect running through diffuse intracellular signalling can survive extreme truncation. MT-2 at 1024.2 daltons is seven residues plus a lactam bridge, a D-amino acid and two capped termini, because receptor engagement requires enough structure to present a specific surface. What a fragment needs to be depends entirely on what the retained function requires, and these two are as clean an illustration of that as this catalogue contains.

Research applications

▸Multi-component connective tissue research protocols
▸Comparative work on three-component versus four-component combinations
▸Co-lyophilisation and multi-component dissolution methodology
▸Copper peptide compatibility studies
▸Surface adsorption behaviour across a wide molecular size range
▸Anti-inflammatory and matrix pathway research

Handling checklist

✓Verify KPV as Lys-Pro-Val at 342.43 Da, CID 125672 - never by searching 'KPV'
✓Verify GHK-Cu against 402.92 Da (CID 71587328), not 340.38 for free GHK
✓Verify TB-500 against 889.0 Da, not 4.9 kDa for thymosin beta-4
✓Verify BPC-157 against 1419.5 Da
✓Expect four separate certifications - a single combined purity figure is a category error
✓Allow more dissolution time than a three-component blend; do not draw before it completes
✓Use low-binding consumables - KPV is the component most lost to surfaces
✓Store lyophilised, cold, dry and dark; the copper complex governs light protection

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Drawing from a partly dissolved four-component cake

Fix: Components dissolve in sequence across a fourfold size range. An early sample is enriched in fast components and depleted in slow ones, with no visible sign.

✗ Verifying the KPV component by searching 'KPV' in PubChem

Fix: That returns 2-oxo-5-phenylpentanoic acid at 192.21 Da, an unrelated compound. Search Lys-Pro-Val for CID 125672.

✗ Assuming the 10mg difference from GLOW is 10mg of KPV

Fix: Not stated. It could be added KPV with the others unchanged, or a redistribution across all four.

✗ Treating four component literatures as evidence about the blend

Fix: No published work addresses this combination or any subset of it. Summing separate literatures produces no evidence about a mixture.

✗ Adding a chelator because the blend contains copper

Fix: Unnecessary. None of the four components contains cysteine or methionine, so copper-catalysed oxidation has no substrate here.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is this specific to KLOW?: No, it applies to any fixed-ratio mixture of molecules with different stability, which is nearly all of them. It is more pronounced here because four components span a wide range of size and structural protection.
Do any of these have published half-life figures?: The individual literatures contain stability and persistence information of varying quality, generated in different systems under different conditions. None of it was generated with the components in combination, which is the situation a blend creates.
Could the components stabilise each other?: That is a real possibility in principle - competition for the same peptidases would slow all of them - and it is untested here. It would push in the opposite direction to the divergence described above, which is a reason to measure rather than to assume either way.
Does this affect storage as well?: Storage is a separate and better-understood problem, covered elsewhere in this category. The point here concerns what happens after a solution leaves the vial, where the conditions are no longer controlled by handling.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More KLOW (Blend) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum